翰森制药：HS-10365胶囊上市许可申请获受理

Core Viewpoint - Hansoh Pharmaceutical (03692.HK) has received acceptance for its application for marketing authorization of the high-selectivity RET inhibitor HS-10365 capsules from the National Medical Products Administration, aimed at treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive [1] Company Overview - Hansoh Pharmaceutical is an innovation-driven pharmaceutical company that has consistently ranked among the top 100 global pharmaceutical companies for several years [1] - The company has developed a total of 7 innovative drugs that generate sales revenue in China, establishing a rich product pipeline [1]